An experimental cancer drug has had a remarkable success rate with it appearing to cure practically every patient during a clinical trial.
The drug dostarlimab was given to 18 people with a type of rectal cancer every three weeks for six months in a study at the Memorial Sloan Kettering Cancer Center (MSKCC) in New York.
The drug seemed to remove the rectal cancer with minimal side effects although scientists are saying it is too early to say if the patients are totally cured.
